Quantcast

Latest Prostate-specific antigen Stories

2014-10-22 08:27:56

NEW YORK, Oct. 22, 2014 /PRNewswire/ -- New test innovations will be the source of revenue growth in the in vitro diagnostic (IVD) test industry, especially as companies struggle with reimbursement challenges, according to Kalorama Information. The healthcare market researcher listed more than 25 testing innovations in important disease areas in academic settings that could be the future of IVD products. Kalorama details the new approaches its biennial survey of the IVD industry, The...

2014-09-29 08:31:04

Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD CITY, Calif., Sept. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University...

2014-09-29 08:29:46

Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress TORONTO, Sept. 29, 2014 /CNW/ - A final analysis of the Phase 3 COU-AA-302 trial presented at the European Society for Medical Oncology (ESMO) conference in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to...

2014-09-28 08:21:14

Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept. 28, 2014 /PRNewswire/ -- A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men...

2014-09-24 12:29:06

WASHINGTON, Sept. 24, 2014 /PRNewswire-USNewswire/ -- ZERO - The End of Prostate Cancer recently announced the donation of two mobile health vehicles to LSU Health Sciences Center and Buddhist Tzu Chi Medical Foundation. Through a competitive process, the vehicles have been awarded to two reputable health service providers. Both institutions that share ZERO's mission and will leverage the donation to ensure high-risk men continue to receive free prostate cancer testing via the mobile...

2014-09-22 08:27:42

-- Free Or Low Cost Screenings Help To Diagnose Second Leading Cause of Death Among Men Which Can Be Easily Treated If Caught Early -- DENVER, Sept. 22, 2014 /PRNewswire-USNewswire/ -- Prostate cancer is the second leading cause of cancer death in men, but it is easily treated when caught early - the problem is that too often it is not. That is why the Prostate Conditions Education Council (PCEC), - a national organization committed to men's health and a leader in prostate cancer...

2014-09-18 08:29:25

Key evaluation to inform the US Food and Drug Administration regulatory submission SYDNEY, Sept. 18, 2014 /PRNewswire/ -- Australian biomarker discovery company Minomic International Ltd will today launch an important US trial of its MiStat(TM) prostate cancer screening test, planning to achieve US Food and Drug Administration (FDA) regulatory approval upon completion. Minomic's proprietary MiStat(TM) technology is a screening assay capable of identifying the presence of a...

2014-09-17 08:30:32

Proprietary genomic-based VPAC1 cancer biomarker to be co-developed worldwide? PARK CITY, Utah, Sept. 17, 2014 /PRNewswire/ -- NuView Life Sciences, Inc. (NuView) announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to further develop and commercialize NuView's investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate. The agreement also includes all other future...

2014-09-11 12:27:33

SANTA MONICA, Calif., Sept. 11, 2014 /PRNewswire-USNewswire/ -- The Prostate Cancer Foundation (PCF) has awarded 27 new Young Investigator Awards selected from 16 countries to advance new drug discovery, immunotherapy, nutritional sciences, and diagnostics for precision medicine. Young Investigator (YI) Awards stand out among PCF's prestigious research programs, and serve to jumpstart the research careers of recent MDs and PhDs. These 3-year awards are game-changing investments that...

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.